The estimated Net Worth of Scott C. Johnson is at least $1.12 Миллион dollars as of 11 September 2019. Mr. Johnson owns over 7,500 units of Exact Sciences stock worth over $1,015,533 and over the last 6 years he sold EXAS stock worth over $108,671. In addition, he makes $0 as Senior Vice President и Research and Development at Exact Sciences.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Johnson EXAS stock SEC Form 4 insiders trading
Scott has made over 3 trades of the Exact Sciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of EXAS stock worth $480,900 on 11 September 2019.
The largest trade he's ever made was exercising 7,500 units of Exact Sciences stock on 11 September 2019 worth over $480,900. On average, Scott trades about 4,064 units every 66 days since 2019. As of 11 September 2019 he still owns at least 15,838 units of Exact Sciences stock.
You can see the complete history of Mr. Johnson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Scott Johnson biography
Scott Johnson serves as Senior Vice President, Research and Development of the Company. He has served as our Senior Vice President, Research & Development since September 2017. He joined us from Luminex Corporation, a molecular diagnostic product and life sciences tools manufacturer, where he served as Vice President—Assay Research & Development from 2014 to 2017 and as Vice President—Product Development & Manufacturing from 2011 to 2014. Prior to EraGen Biosciences' acquisition by Luminex, Dr. Johnson served as EraGen Biosciences' Vice President—Product from 2008 to 2011. Dr. Johnson earned a bachelor's degree in biotechnology from Rochester Institute of Technology, a doctorate in cellular and molecular biology from University of Wisconsin—Madison and an MBA from the Kellogg Graduate School of Management at Northwestern University.
How old is Scott Johnson?
Scott Johnson is 50, he's been the Senior Vice President и Research and Development of Exact Sciences since 2017. There are 21 older and 4 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.
What's Scott Johnson's mailing address?
Scott's mailing address filed with the SEC is C/O EXACT SCIENCES CORP., 441 CHARMANY DRIVE, MADISON, WI, 53719.
Insiders trading at Exact Sciences
Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania и Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.
What does Exact Sciences do?
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
What does Exact Sciences's logo look like?
Complete history of Mr. Johnson stock trades at Exact Sciences
Exact Sciences executives and stock owners
Exact Sciences executives and other stock owners filed with the SEC include:
-
Kevin Conroy,
Chairman of the Board, President, Chief Executive Officer -
Mark Stenhouse,
General Manager - Screening -
Jeffrey Elliott,
Chief Financial Officer -
D. Scott Coward,
Senior Vice President, Chief Administrative Officer, General Counsel, Secretary -
Jake Orville,
General Manager - Pipeline -
Ana Hooker,
Senior Vice President, Operations -
Graham Lidgard,
Senior Vice President, Chief Scientific Officer -
Kevin T. Conroy,
Chairman, Pres & CEO -
G. Bradley Cole,
Gen. Mang. of Precision Oncology -
Mark Stenhouse,
Advisor -
Graham P. Lidgard,
Emeritus Chief Science Officer -
Jeffrey T. Elliott CFA,
Exec. VP, CFO & COO -
D. Scott Coward,
Chief Admin. Officer, Exec. VP, Gen. Counsel & Sec. -
Kathleen Sebelius,
Independent Director -
Andrew Slavitt,
Director -
Pierre Jacquet,
Independent Director -
Jake Orville,
Gen. Mang. of Pipeline -
Ana Hooker,
Sr. VP of Operations -
James Doyle,
Independent Director -
Michael Wyzga,
Independent Director -
Daniel Levangie,
Independent Director -
Katherine Zanotti,
Independent Director -
Thomas Carey,
Independent Director -
Shacey Petrovic,
Director -
Gisela Paulsen,
General Manager - Precision Oncology -
Torsten Hoof,
General Manager - International -
Freda Lewis-Hall,
Independent Director -
Scott Johnson,
Senior Vice President, Research and Development -
Vic Parker,
Head of Sales -
Tim Caprez,
Chief Compliance Counsel & VP -
Megan Jones,
Associate Mang. of Investor Relations -
Dr. Scott C. Johnson Ph.D.,
Chief Science Officer and Sr. VP of R&D -
Gary Frings,
Chief Information Officer -
Lionel Sterling,
Director -
John A. Fallon,
Director -
David Thompson,
Director -
G Bradley Cole,
General Manager - Diagnostics -
Paul J Clancy,
-
Michael J Barber,
-
Eli Casdin,
Director -
Anthony P Shuber,
Executive Vice President -
John A Jr Mccarthy,
Chief Financial Officer -
Don M Hardison,
President, CEO and Director -
Barry M Berger,
SVP, Chief Medical Officer -
William J. Megan,
SVP, Finance & PFO -
John K Bakewell,
Chief Financial Officer -
Jeffrey R Luber,
General Counsel -
Edwin M Jr Kania,
Director -
Charles R Jr Carelli,
Prin. Acct. Off. & Corp. Ctlr. -
Patrick J Zenner,
Director -
Stanley N Lapidus,
Director -
John M Krayacich,
SVP, Sales and Marketing -
Richard W Barker,
Director -
Laura S Stoltenberg,
Chief Commercial Officer -
Cornelius Iii Mcgillicudy,
Director -
Harry W Wilcox,
Senior Vice President and CFO -
Lance Willsey,
Director -
Michael E Singer,
Director -
Maneesh Arora,
Vice President -
James P Connelly,
Director -
Sally Crawford,
Director -
Sarah Condella,
EVP, Human Resources -
Timothy J Scannell,
Director -
James Herriott,
SVP, General Counsel & Sec -
Everett Cunningham,
Chief Commercial Officer -
Jacob A Orville,
EVP, GM, Screening -
Brian Baranick,
EVP, GM, Precision Oncology